Evidence map›Paper›PMID 42588465›Full record

ReviewMolecules (Basel, Switzerland)2026

Catalytic Enantioselective Construction of Carbon-Sulfur Bonds: Recent Advances and Future Perspectives.

Michał Rachwalski

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Michał RachwalskiDepartment of Organic and Applied Chemistry, Faculty of Chemistry, University of Lodz, Tamka 12, PL-91-403 Lodz, Poland.ORCID 0000-0003-4803-8078

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The catalytic enantioselective formation of carbon-sulfur (C-S) bonds is a rapidly evolving field in modern organic synthesis, driven by the importance of chiral sulfur-containing motifs in pharmaceuticals, agrochemicals, and functional materials. Despite their significance, asymmetric C-S bond-forming reactions remain challenging due to the strong coordinating ability and nucleophilicity of sulfur species, catalyst deactivation, and difficulties in controlling sulfur- or carbon-centered stereogenicity. Recent advances in transition-metal catalysis, organocatalysis, and emerging electrocatalytic strategies have enabled efficient access to diverse chiral organosulfur frameworks, including sulfides, sulfoxides, sulfilimines, sulfoximines, and sulfinamides, with high levels of enantioselectivity. These methodologies have significantly expanded the synthetic toolbox for constructing C-S bonds under mild and sustainable conditions. This review provides a concise and critical overview of catalytic enantioselective C-S bond formation, emphasizing reaction design, catalytic systems, and mechanistic aspects of enantiocontrol. Key transformations such as asymmetric allylic substitution, conjugate addition, cross-coupling, photoredox-enabled processes, and emerging electrochemical approaches are discussed. Particular attention is given to strategies for the generation and control of sulfur-centered stereogenicity. Finally, current limitations and future opportunities, including dual catalysis, late-stage functionalization, and sustainable catalytic systems, are highlighted to guide further developments in asymmetric organosulfur chemistry.

Indexed as

asymmetric synthesiscarbon–sulfur bond formationenantioselective catalysisorganocatalysisorganosulfur compoundsphotoredox catalysissulfoximinessulfur chemistrysulfur stereogenicitytransition-metal catalysis

Identifiers

PMID42588465
PMCPMC13468344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.